Skip to content

US · MRVI · BIOTECHNOLOGY

Maravai LifeSciences Holdings, Inc. (MRVI) intrinsic value and stock valuation

$6.98as of 2026-11-21 · Mkt cap 1.72B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Maravai LifeSciences Holdings, Inc. DCF and intrinsic value

InvestorsCraft values MRVI with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from MRVI’s statements →

Maravai LifeSciences Holdings, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Diego, CA 92121 maravai.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$185.7M-8.1% 5y CAGRd
20182025
Net income
-$-130.77M
20182025
Free cash flow
-$-70.72M
20182025
Total equity
$372.7M+19.2% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$185.7M$259.2M$288.9M$883M$799.2M
Operating income-$-6.74M-$-235.62M-$-31.65M$574.2M$554.6M
Net income-$-130.77M-$-144.85M-$-119.03M$220.2M$182M
EPSd-$-901.43K-$-1.05M-$-902.29K$1.67M$1.49M
Operating cash flow-$-57.57M$7.46M$126.2M$536M$368.6M
Capital expenditure-$-13.15M-$-29.66M-$-65.55M-$-17.09M-$-14.85M
Free cash flow-$-70.72M-$-22.19M$60.7M$518.9M$353.7M
Total assets$770.6M$1.01B$1.49B$2.28B$1.92B
Total debt$35.6M$376.7M$611M$585.3M$575.2M
Net debt-$-181.31M$54.3M$36M-$-46.88M$24M
Total equity$372.7M$577.2M$789.9M$905.2M$545.4M
Cash and short-term investments$216.9M$322.4M$575M$632.1M$551.3M
Income statement
20252024202320222021
Revenue$185.7M$259.2M$288.9M$883M$799.2M
Cost of revenue$152.4M$150.9M$148.7M$169M$140.6M
Gross profit$33.4M$108.3M$140.2M$714M$658.7M
Research and development expenses$23.3M$19.2M$17.3M$18.4M$15.2M
Selling, general and administrative expenses$171.5M$161.8M$151.4M$129.3M$100.1M
Other expenses-$-154.67M$162.9M$3.18M-$-7.8M-$-11.25M
Operating expenses$40.1M$343.9M$171.9M$139.8M$104M
Cost and expenses$192.5M$494.8M$320.6M$308.8M$244.6M
Interest income$24M$27.4M$27.7M$2.34M$0.00
Interest expense$27M$47.7M$45.9M$20.4M$30.3M
Depreciation and amortization$60.9M$56.9M$48.8M$38.1M$24.8M
Ebitda-$-147.11M-$-156.92M$712.4M$610M$585.8M
Operating income-$-6.74M-$-235.62M-$-31.65M$574.2M$554.6M
Total other income/expenses, net-$-228.24M-$-25.86M$649.4M-$-22.74M-$-23.88M
Income before tax-$-234.97M-$-261.48M$617.7M$551.5M$530.8M
Income tax expense-$-4.21M-$-1.86M$756.1M$60.8M$61.5M
Net income-$-130.77M-$-144.85M-$-119.03M$220.2M$182M
Weighted average shares outstanding$145.1M$137.9M$131.9M$131.5M$114.8M
Weighted average diluted shares outstanding$145.1M$137.9M$131.9M$131.7M$122M
Balance sheet
20252024202320222021
Cash and short-term investments$216.9M$322.4M$575M$632.1M$551.3M
Net receivables$25.5M$38.5M$55.7M$146.8M$117.5M
Inventory$40.5M$50.1M$51.4M$43.2M$51.6M
Total current assets$296.3M$429.2M$699.9M$847.9M$740M
Property, plant and equipment, net$1.22M$217M$222.7M$116.6M$95.4M
Goodwill and intangible assets$281M$354.8M$547M$500.3M$270.3M
Long-term investments$0.00$0.00$8.56M$11.4M$0.00
Total non-current assets$474.3M$579.1M$787.5M$1.43B$1.18B
Total assets$770.6M$1.01B$1.49B$2.28B$1.92B
Accounts payable$0.00$12M$10.7M$5.99M$8.15M
Short-term debt$5.44M$13.7M$12.9M$11.7M$9.72M
Deferred revenue$0.00$3.29M$3.36M$3.09M$12.6M
Total current liabilities$44.9M$57M$87.5M$110.1M$93.8M
Long-term debt$30.1M$363M$598.1M$573.6M$565.5M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$353M$374.1M$610.1M$1.27B$1.28B
Capital lease obligations$0.00$80.8M$86.8M$57.8M$44.6M
Total liabilities$397.9M$431M$697.6M$1.38B$1.37B
Common stock$2.56M$2.53M$2.51M$2.55M$2.55M
Retained earnings$10.1M$140.9M$285.7M$404.8M$184.6M
Accumulated other comprehensive income (loss)$520K$0.00$0.00$0.00$0.00
Total equity$372.7M$577.2M$789.9M$905.2M$545.4M
Total investments$0.00$0.00$8.56M$11.4M$0.00
Total debt$35.6M$376.7M$611M$585.3M$575.2M
Net debt-$-181.31M$54.3M$36M-$-46.88M$24M
Cash flow statement
20252024202320222021
Net income-$-130.77M-$-259.62M-$-119.03M$490.7M$469.3M
Depreciation and amortization$60.5M$56.9M$48.8M$38.1M$24.8M
Stock-based compensation$0.00$49.4M$34.6M$18.7M$10.5M
Change in working capital-$-7.98M-$-12.61M$97.8M-$-45.08M-$-176.63M
Accounts receivable$12.8M$14.4M$84.4M-$-22.27M-$-70.39M
Inventory$8M$380K$650K$9.46M-$-21.57M
Accounts payable-$-7.35M$720K$5.28M-$-1.58M$680K
Net cash provided by operating activities-$-57.57M$7.46M$126.2M$536M$368.6M
Investments in property, plant and equipment-$-13.15M-$-29.66M-$-65.55M-$-17.09M-$-14.85M
Acquisitions, net-$-18.26M$0.00-$-69.62M-$-238.35M$120M
Net cash used for investing activities-$-31.41M-$-24.32M-$-122.31M-$-267.61M$105.7M
Common stock issued$0.00$0.00$0.00$2.36M$1.71M
Common stock repurchased$0.00-$-2.08M-$-20K$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-16.5M-$-235.71M-$-61.09M-$-187.5M-$-159.05M
Net change in cash-$-105.51M-$-252.56M-$-57.18M$80.9M$315.1M
Cash at end of period$216.9M$322.4M$575M$632.1M$551.3M
Operating cash flow-$-57.57M$7.46M$126.2M$536M$368.6M
Capital expenditure-$-13.15M-$-29.66M-$-65.55M-$-17.09M-$-14.85M
Free cash flow-$-70.72M-$-22.19M$60.7M$518.9M$353.7M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Maravai LifeSciences Holdings, Inc.

        Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases. Its diverse product line supports critical stages of biopharmaceutical development, featuring nucleic acids for both diagnostic and therapeutic applications, antibody-based solutions for detecting impurities in biopharmaceutical manufacturing, and tools for monitoring protein expression across different tissue types. The company conducts its operations through two distinct segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment specializes in manufacturing and distributing products integral to gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics. This encompasses reagents utilized in the chemical synthesis, modification, labeling, and purification of DNA and RNA. Additionally, this division provides messenger RNA, oligonucleotides, their foundational building blocks, plasmid DNA, and the proprietary CleanCap capping technology. Meanwhile, the Biologics Safety Testing segment offers analytical products vital for developing biologic manufacturing processes. Its offerings include bespoke antibody and assay development services tailored to specific products, alongside HCP ELISA kits, various other ELISA kits for identifying bioprocess impurities and contaminants, ancillary reagents, and custom service solutions. Maravai's clientele spans biopharmaceutical companies, other life sciences and biopharmaceutical research firms, academic research institutions, and in vitro diagnostics companies. Incorporated in 2020, Maravai LifeSciences Holdings, Inc. maintains its headquarters in San Diego, California.

        CEO
        Bernd Brust
        Employees
        435
        Beta
        0.58

        Explore

        Frequently asked questions

        What is the intrinsic value of Maravai LifeSciences Holdings, Inc. (MRVI)?

        Maravai LifeSciences Holdings, Inc. (MRVI) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is MRVI undervalued?

        MRVI trades at a price of $6.98 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.